EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

Craig M McDonald, Michela Guglieri, Dragana Vučinić, Gyula Acsadi, John F Brandsema, Claudio Bruno, Erika L Finanger, Amy Harper, Mercedes Lopez Lobato, Riccardo Masson, Nuria Muelas, Francina Munell und 16 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70165 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Craig M McDonald und 27 weiteren Autor:innen. Beteiligte Einrichtung: University of California Davis Health, Sacramento, California, USA. Hauptthemen laut MEDLINE: Carbamates, Histone Deacetylase Inhibitors, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, Italfarmaco.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD).

Methods

The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS]), receiving givinostat or placebo, or were successfully screened but not randomized into EPIDYS. All receive givinostat oral suspension open‐label at a flexible, weight‐based dose in addition to systemic corticosteroids, and attend visits every 4 months.

Results

A total of 194 patients are included in the current analyses, with a mean duration of givinostat exposure (excluding use in prior studies) of 559.6 days (SD 373.0); when including use in the prior studies, the maximum exposure to givinostat was > 8 years. Although the majority of patients reported ≥ 1 adverse event (169/194 [87.1%]), most were mild/moderate in severity, and the safety profile of givinostat was consistent with prior studies. Post hoc comparisons with natural history datasets (ImagingDMD and CINRG) suggest, in propensity matched populations, givinostat added to systemic corticosteroids significantly delayed the loss of the ability to rise from the floor, the loss of the ability to complete the 4‐stair climb test, and the loss of ambulation (by medians of 2.0–3.3 years; all nominal p < 0.05).

Interpretation

Overall, the safety and tolerability of long‐term administration of givinostat in patients with DMD was consistent with previous studies. Comparisons with natural history data suggest that givinostat delays the occurrence of major disease progression milestones. Trial Registration EudraCT number: 2017‐000397‐10; ClinicalTrials.gov identifier: NCT03373968

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamatesHistone Deacetylase InhibitorsMuscular Dystrophy, DuchenneAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultDisease Progression

Stichwörter der Autor:innen

Duchenne muscular dystrophyefficacylong termsafety

Substanzen

CarbamatesgivinostatHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • University of California Davis Health, Sacramento, California, USA.
  • The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Clinic for Neurology and Psychiatry for Children and Youth, Belgrade, Serbia.
  • Division of Neurology, Connecticut Children's, Hartford, Connecticut, USA.
  • Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Förderung

  • NIAMS NIH HHS
  • NIH HHS
  • Italfarmaco
  • National Institutes of Health

Zitieren

APA

McDonald, C. M., Guglieri, M., Vučinić, D., Acsadi, G., Brandsema, J. F., Bruno, C., Finanger, E. L., Harper, A., Lobato, M. L., Masson, R., Muelas, N., Munell, F., Nevo, Y., Péréon, Y., Phan, H., Sansone, V. A., Scoto, M., Willis, T., Finkel, R. S., …, & ImagingDMD Investigators (2025). Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70165

Vancouver

McDonald CM, Guglieri M, Vučinić D, Acsadi G, Brandsema JF, Bruno C, et al. Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70165

BibTeX
@article{McDonald2025,
  author = {McDonald, Craig M and Guglieri, Michela and Vučinić, Dragana and Acsadi, Gyula and Brandsema, John F and Bruno, Claudio and Finanger, Erika L and Harper, Amy and Lobato, Mercedes Lopez and Masson, Riccardo and Muelas, Nuria and Munell, Francina and Nevo, Yoram and Péréon, Yann and Phan, Han and Sansone, Valeria A and Scoto, Mariacristina and Willis, Tracey and Finkel, Richard S and Vandenborne, Krista and Cazzaniga, Sara and Montrasio, Silvia and Alessi, Federica and Bettica, Paolo and Mercuri, Eugenio and Givinostat Study 51 Investigators, Givinostat Study 51 Investigators and Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators, Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators and ImagingDMD Investigators, ImagingDMD Investigators},
  title = {Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70165}
}
Kostenlos starten →